Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-2000 in Contact Hypersensitivity
NCT03089775Phase 1Completed
- Sponsor
- Fresh Tracks Therapeutics
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBI-2000 in contact dermatitis (3 cohorts), sponsored by Fresh Tracks Therapeutics. Primary endpoints: Number of adverse events in each study group at 4 weeks, Vital signs, physical examinations, ECG, blood analysis, urine analysis at 4 weeks and 1 more. Started Mar 2017; status: completed.
02
Drugs
BBI-2000
03
Conditions
contact dermatitis
Beyond the preview
Go deeper on NCT03089775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089775.